Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Deals Of The Week: Stromedix/UCSF, Pfizer/UCSF, Sekisui/Genzyme

  • News

Executive Summary

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.

You may also be interested in...



J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business

The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.

US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say

US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.

Vir Says Its Best-In-Class COVID-19 Antibody Profile Is Holding Up

Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By